Leukemia Insights Newsletter
Our Leukemia Insights e-newsletter, started in 2007 by Hagop Kantarjian, M.D., sponsored in part by the Charif Souki Cancer Research Fund, focuses on our various therapy options. A special thanks to Mary Alma Welch and Lisa Palacios for their continued work on this important publication.
All issues of Leukemia Insights are in PDF format. Contact us for archived issues.
2024
- April - Update on the management of and clinical trials for chronic myeloid leukemia
- March - Clinical trials for patients with myelofibrosis: Established approaches and new paradigms
- February - Clinical Trials for Patients with Myeloproliferative Neoplasms: Spotlight on Polycythemia Vera and Essential Thrombocytosis
- January - Novel Approaches for the Treatment of Adult Acute Lymphoblastic Leukemia (ALL) in 2024
2023
- October - Myeloproliferative Neoplasm Clinical Trials: Focus on Polycythemia Vera and Essential Thrombocytosis
- September - TP53-Directed Therapies for AML and MDS
- August - Chronic Lymphocytic Leukemia – Next Steps
- July - Menin Inhibitors: Monotherapy and Combination Studies A New Class of Targeted Therapy for Acute Leukemia
- June - MRD Eradication and Maintenance Strategies in Acute Myeloid Leukemia
- May - Novel Combination Therapies for Patients with Myelofibrosis (MF): A New Era of Clinical Trials in the MPN Field
- April - Treatment for Richter Transformation
- March - Novel Approaches for the Treatment of ALL in Adults in 2023
- February - Clinical Trials Update: Myeloproliferative Neoplasms
- January - Progress with FLT3 Inhibitors in Acute Myeloid Leukemia (AML)
2022
- December - An update on the MDS program at MD Anderson
- November - Clonal Hematopoiesis
- October - Update of the management and clinical trials for chronic myeloid leukemia
- September - Treatment for Richter transformation – an update
- August - Spotlight on rare hematologic malignancies: Development of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program key updates & insights
- July - Novel strategies in development for treatment of myelofibrosis
- June - Novel approaches for the treatment of ALL in adults in 2022
- May - Relapsed and refractory chronic lymphocytic leukemia (CLL) - next steps
- April - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): exciting progress in a rare disease field
- March - Clinical trials for patients with polycythemia vera (PV), essential thrombocythemia (ET), systemic mastocytosis (SM) and myeloid/lymphoid neoplasms with eosinophilia (MLNEo)
- February - Progress in myelodysplastic syndromes at MD Anderson
- January - Novel Approaches for the Treatment of ALL in Adults in 2022
2021
- December - Menin inhibitors: a new class of targeted therapy for treatment of acute leukemia
- November - Management of clonal hematopoiesis in cancer patients
- October - Immunotherapies and Cellular Therapies for Patients with Acute Myeloid Leukemia
- September - Promising Novel Treatments in Clinical Development for Myelofibrosis
- August - Novel approaches for the treatment of ALL in adults in 2021
- July - Treatment for Richter Transformation – finally, a new hope emerges
- June - Spotlight on rare, atypical, myeloid neoplasms: systemic mastocytosis and myeloid/lymphoid neoplasms with eosinophilia and FGFR1 rearrangements
- May - Targeting the p-D-C with C-D-1-2-3 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and p-DC Acute Myeloid Leukemia (AML)
- April - Oral Therapies for Acute Myeloid Leukemia (AML)
- March - FLT3 Inhibitors in Acute Myeloid Leukemia (AML)
2020
- December - Novel approaches for patients with Philadelphia chromosome-positive ALL
- October - Chimeric Antigen Receptor (CAR) Therapies for Patients with Acute Lymphoblastic Leukemia (ALL)
- September - Entering a New Era in Myeloproliferative Neoplasms (MPN) Research with Multiple Phase 3 and Other Pivotal Clinical Trials
- August - Treatment Strategies for Chronic Myelomonocytic Leukemia (CMML)
- July - Myelodysplastic syndrome (MDS) Clinical Trial Program at MD Anderson
- June - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Novel Therapeutic Approaches for a Rare Hematologic Malignancy
- April - FLT3 Inhibitors in Acute Myeloid Leukemia
- January - Novel Approaches for the Treatment of ALL in Adults in 2020
2019
- November - Novel Targeted Therapies for Patients with Acute Myeloid Leukemia (AML)
- October - Focus on Rare Blood Cancers: Novel Therapies and Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm
- September - Innovative Treatment Strategies for Classic and Atypical Myeloproliferative Neoplasms
- August - Current Treatment Options for Patients with Chronic Lymphocytic Leukemia
Subscribe to Leukemia Insights
Leukemia Clinical Trials
Stay Connected
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.